You are here: Industry Insights > Acorda

News List

Catalent Acquires Acorda’s INBRIJA Manufacturing Operations contractpharma
January 14, 2021
The CDMO pays $80 million for dry powder inhaler spray drying, capsule manufacturing and packaging operations in Boston area.
Acorda's sales team switches gears to push crucial Parkinson's launch Inbrija fiercepharma
January 17, 2019
True to its word, Acorda has moved its entire salesforce over from generics-plagued Ampyra to new Parkinson’s launch Inbrija. But it’s not relying solely on that team to get the ball rolling.
Batycky exits Acorda to head up new biotech fiercebiotech
August 15, 2018
Acorda Therapeutics’ chief technology officer, Rick Batycky Ph.D., is leaving the company next week after four years in the role to head up his own operation.
Acorda drops experimental Parkinson’s drug pharmatimes
November 22, 2017
US biotech Acorda Therapeutics is discontinuing development of its experimental Parkinson’s disease therapy tozadenant on concerns over patient safety.
Acorda Takes a $363M Hit as Deaths Lead to Termination of Parkinson's Drug biospace
November 21, 2017
Acorda Therapeutics reported that it had ended enrollment in its Phase III clinical trial of tozadenant for Parkinson’s disease due to several patient deaths. Today, the company announced that it was discontinuing clinical development of the drug altogeth
Drugmaker Acorda suffers after deaths in Parkinson's Trial biospectrumasia
November 20, 2017
The company did not specify how many of the patients who died had agranulocytosis
5 Deaths Force Acorda to Stop Enrollment in Phase III Parkinson's Trial biospace
November 17, 2017
Acorda Therapeutics updated its Phase III clinical trial of tozadenant for Parkinson’s disease. Enrollment has been halted for new patients due to several deaths, and changes in the program have been made related to safety issues.
Activist pushes Acorda to sell, figuring pipeline's too risky to offset Ampyra loss fiercepharma
August 08, 2017
A New York hedge fund, Scopia Capital Management, wants Acorda to put itself up for sale
Acorda Submits New Drug Application to U.S. Food and Drug Administration for INBRIJA firstwordpharma
June 30, 2017
Acorda Submits New Drug Application to U.S. Food and Drug Administration for INBRIJA
Acorda's experimental Parkinson's disease drug CVT-301 hits main goal of late-stage trial firstwordpharma
February 10, 2017
Acorda Therapeutics' experimental drug CVT-301 demonstrated a significant improvement in motor function versus placebo in people with Parkinson's disease experiencing OFF periods in a Phase III study, the company reported.